Institute for Experimental Cellular Therapy, University Hospital Essen, Essen, Germany.
Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands.
Blood. 2021 Feb 18;137(7):923-928. doi: 10.1182/blood.2020008464.
In hematopoietic cell transplantation (HCT), permissive HLA-DPB1 mismatches between patients and their unrelated donors are associated with improved outcomes compared with nonpermissive mismatches, but the underlying mechanism is incompletely understood. Here, we used mass spectrometry, T-cell receptor-β (TCRβ) deep sequencing, and cellular in vitro models of alloreactivity to interrogate the HLA-DP immunopeptidome and its role in alloreactive T-cell responses. We find that permissive HLA-DPB1 mismatches display significantly higher peptide repertoire overlaps compared with their nonpermissive counterparts, resulting in lower frequency and diversity of alloreactive TCRβ clonotypes in healthy individuals and transplanted patients. Permissiveness can be reversed by the absence of the peptide editor HLA-DM or the presence of its antagonist, HLA-DO, through significant broadening of the peptide repertoire. Our data establish the degree of immunopeptidome divergence between donor and recipient as the mechanistic basis for the clinically relevant permissive HLA-DPB1 mismatches in HCT and show that permissiveness is dependent on HLA-DM-mediated peptide editing. Its key role for harnessing T-cell alloreactivity to HLA-DP highlights HLA-DM as a potential novel target for cellular and immunotherapy of leukemia.
在造血细胞移植(HCT)中,与非允许性错配相比,患者与其无关供体之间允许性 HLA-DPB1 错配与改善的结果相关,但潜在的机制尚不完全清楚。在这里,我们使用质谱、T 细胞受体-β(TCRβ)深度测序和同种异体反应性的体外细胞模型来探究 HLA-DP 免疫肽组及其在同种异体反应性 T 细胞反应中的作用。我们发现,与非允许性错配相比,允许性 HLA-DPB1 错配显示出明显更高的肽库重叠,导致健康个体和移植患者中同种异体反应性 TCRβ 克隆型的频率和多样性降低。通过 HLA-DM 缺失或其拮抗剂 HLA-DO 的存在,可以反转允许性,从而显著拓宽肽库。我们的数据确定了供体和受者之间免疫肽组差异的程度,作为 HCT 中临床相关允许性 HLA-DPB1 错配的机制基础,并表明允许性取决于 HLA-DM 介导的肽编辑。其对利用 T 细胞同种异体反应性来调节 HLA-DP 的关键作用突显了 HLA-DM 作为白血病的细胞和免疫治疗的潜在新靶点。